Stock News

BioSyent Inc. (RX) EPS Estimated At $0.12

Analysts expect BioSyent Inc. (CVE:RX) to report $0.12 EPS on November, 21.They anticipate $0.03 EPS change or 33.33 % from last quarter’s $0.09 EPS. V_RX’s profit would be $1.74 million giving it 18.85 P/E if the $0.12 EPS is correct. After having $0.11 EPS previously, BioSyent Inc.’s analysts see 9.09 % EPS growth. The stock decreased 1.63% or $0.15 during the last trading session, reaching $9.05. About 2,500 shares traded. BioSyent Inc. (CVE:RX) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company has market cap of $131.42 million. The Company’s products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of papillary non-muscle invasive bladder cancer. It has a 23.82 P/E ratio. The company's products also comprise Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; and endoscopies, proctoscopies, rectoscopies, and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*